Shortage of diabetes drug flagged until 2023 While semaglutide supply will be intermittent, its current availability should be ‘enough for approved use’, the manufacturer has advised.
‘Nonsensical’ to stop GPs approving access to glucose monitors The decision to block GPs from certifying patient access to the devices ‘needs to be reviewed and rectified,’ the RACGP president says.
CVD and diabetes rates spike post-COVID: Study The risk of contracting diabetes is especially high in the first four weeks after infection, but returns to baseline within months.
Huge spike in diabetes diagnoses in past two decades The percentage of the Australian population living with diabetes has increased significantly in the past two decades, new AIHW research suggests.
Unpacking diabetes and the heart SPONSORED: New medicines and emerging strategies to profile risk offer more options than ever to manage CVD risk in people with diabetes.
New diabetes medication shortage will impact patient care The semaglutide shortage is having a flow on effect, with dulaglutide now also in short supply until at least the end of August.
Semaglutide shortage prompts caution around off-label prescribing GPs are being asked to prioritise the drug for people with diabetes, but with supplies critically low, what are the alternatives?
Queensland Health and Pharmacy Guild stonewall queries about UTI pilot evaluation Mystery and confusion surround who has seen the report, when it was completed and if the full results will ever be publicly released.
First consensus statement on T2DM in young adults released The statement contains recommendations that differ from typical management guidelines, but also fails to acknowledge the role of GPs.
Second SGLT2 inhibitor approved for heart failure Empagliflozin has been added to the PBS for symptomatic heart failure with reduced ejection fraction, regardless of diabetes status.